Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 study of Remestemcel-L in non-COVID-19-related ARDS

Next Previous
X
Search
Trial Profile

A Phase 3 study of Remestemcel-L in non-COVID-19-related ARDS

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 13 Dec 2021 According to a Novartis media release, Mesoblast is preparing to initiate a pivotal Phase 3 trial that may support a COVID ARDS EUA
    • 03 Dec 2020 New trial record
    • 19 Nov 2020 According to a Mesoblast, Novartis media release, Novartis intends to initiate a Phase 3 study in non-COVID-19-related ARDS after the anticipated closing of the license agreement and successful completion and outcome of the ongoing study in COVID-19-related ARDS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top